Open in new window
|
|
Featured News
|
|
Thermo Fisher Scientific Gets Extended 510k Clearance of Freelite Assays for Evaluation of MGUS
Thermo Fisher Scientific Inc. has received 510k clearance, following US Food and Drug Administration (FDA) requirements, to market its Optilite Freelite assays’ claim for the evaluation of monoclonal...
Read more
|
|
Pharmaindustrial News
|
|
Inoviv Introduces MasterKey for Multiplexed Targeted Protein Assays
Inoviv has developed MasterKey, which enables researchers to select specific proteins from a comprehensive, pre-characterized catalog of thousands of proteins.
Read more
|
|
|
Waters Introduces New TA Instruments Rapid Screening-DSC for Antibody Drugs
Waters Corporation has launched the TA Instruments Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers.
Read more
|
|
|
Zydus Gets Approval from COFEPRIS to Market Mamitra
Zydus Lifesciences has announced that COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval for Mamitra, a Trastuzumab biosimilar.
Read more
|
|
|
Luye Pharma Gets US FDA Approval of ERZOFRI Extended-Release Injectable Suspension
Luye Pharma Group has announced that the US Food and Drug Administration (FDA) has approved the company's ERZOFRI (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia...
Read more
|
|
|
Strides Pharma Shows Strong Q1FY25 Results with 16.7 Percent of Revenue Growth
Strides Pharma Science Ltd. has announced its consolidated financial results for the quarter (Q1FY25).
Read more
|
|
|
Acumen Announces New Findings from Phase 1 INTERCEPT-AD Study at AAIC 2024
Acumen Pharmaceuticals, Inc. has published new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193).
Read more
|
|
|
Sun Pharma Gets US FDA Approval for LEQSELVI for Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia...
Read more
|
|
Articles
|
|
Comprehensive Overview of Contract Research and Manufacturing Services (CRAMS) in India
India's journey in the Contract Research and Manufacturing Services (CRAMS) industry began in the early 1980s, drawing multinational pharmaceutical companies...
Read more
|
|
Interviews
|
|
Simplify Medical Surgeries with SS Innovations Surgical Robotic System
Q: How can surgical robotics influence the outcomes in complex surgeries like cardiac and thoracic surgery and how is SS Innovations products impacting the...
Read more
|
|
|
|
This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.
Unsubscribe
|